NCT02171741已完成1 期
A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 31
- 主要终点
- Incidence and intensity of AdverseEvents according to Common Terminology Criteria (CTCAE version 3)
研究概览
简要总结
Study to determine the maximum tolerated dose (MTD) for various treatment durations of BIBW 2992 when administered in combination with docetaxel as determined by drug-related adverse events (AEs) as well as Pharmacokinetics, overall safety and antitumor efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with confirmed diagnosis of advanced, non-resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who are amenable to docetaxel, preferably patients with breast, prostate, or non-small cell lung cancer. Patients must have failed prior standard therapies associated with clinical benefits, including survival benefits, if such therapies are available. If docetaxel administration is standard therapy associated with clinical benefits, patients are eligible
- •Age 18 years or older
- •Life expectancy of at least three (3) months
- •Written informed consent that is consistent with International Conference on Harmonization - Good Clinical Practice guidelines
- •Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
- •Patients must have resolution from prior chemo-, hormone-, immuno-, or radiotherapy related toxicities to CTC Grade <= 1or baseline for individual patient
- •Patients must be recovered from previous surgery
排除标准
- •Active infectious disease
- •Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea
- •Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
- •Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least eight weeks, no history of cerebral edema or bleeding in the past eight weeks and no requirement for steroids or anti-epileptic therapy
- •Cardiac left ventricular function with resting ejection fraction ≥ CTC Grade 1
- •Absolute neutrophil count (ANC) less than 1500 / mm3
- •Platelet count less than 100 000 / mm3
- •Bilirubin > upper limit of normal (ULN)
- •Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) > 1.5 x ULN
- •Alkaline Phosphatase > 2.5 x ULN
- •Serum creatinine > 1.5 mg / dl (> 132 μmol / L, SI (Système Internationale) unit equivalent)
- •Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
- •Pregnancy or breast-feeding
- •Concurrent treatment with other investigational drugs, or chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding Luteinizing hormone-releasing hormone agonists, or other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
- •Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before start of therapy or concomitantly with this study (8 weeks for trastuzumab)
- •Patients unable to comply with the protocol
- •Active alcohol or drug abuse
- •Hypersensitivity to docetaxel or any component or other drug formulated with polysorbate 80
- •The patient may be eligible for re-treatment after the previous course is finished. The patient will not be eligible if any of the following conditions are met:
- •If patients' latest X-ray, CT or MRI reveals progressive disease, or if clinical assessment reveals signs of disease progression
- •Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course
- •Patients fulfilling any of the Exclusion Criteria listed before as determined before treatment Day 1 of any new course
- •Patient not recovered from any dose-limiting toxicity (DLT) 14 days after onset. Recovery is defined as a return to baseline level or CTC Grade 1, whichever is higher
研究组 & 干预措施
Docetaxel + BIBW 2992
Experimental
干预措施: BIBW 2992 (Drug)
Docetaxel + BIBW 2992
Experimental
干预措施: Docetaxel (Drug)
结局指标
主要结局
Incidence and intensity of AdverseEvents according to Common Terminology Criteria (CTCAE version 3)
时间窗: up to 32 months
Maximum tolerated dose (MTD) of BIBW 2992
时间窗: up to 126 days
次要结局
- Objective tumor response(up to 32 months)
- Correlation of EGFR (epidermal growth factor receptor), HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses(up to 32 months)
- Area under the plasma concentration-time curve (AUC) for several time points(up to 48 hours after administration)
- The percentage of AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)(up to 48 hours after administration)
- Predose plasma concentration (Cpre) for several time points(predose on day 10 and 21)
- Plasma concentration at 24 hours (C24)(24 hours after the first and the last adminstration of study drug)
- Maximum measured plasma concentration (Cmax) for several time points(up to 48 hours after administration)
- Time from dosing to the maximum plasma concentration (tmax) for several time points(up to 48 hours after administration)
- Terminal half-life (t1/2) for several time points(up to 48 hours after administration)
- Mean residence time (MRT) for several time points(up to 48 hours after administration)
- Apparent clearance (CL/F) for several timt points(up to 48 hours after administration)
- Apparent volume of distribution during the terminal phase (Vz/F) for several time points(up to 48 hours after administration)
- Terminal rate constant in plasma (λz)(up to 48 hours after administration)
- Accumulation ratio between day 1 and day 21 with respect to Cmax (Ra1) and AUC (RA2)(up to day 21)
研究者
相似试验
已完成
1 期
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsNeoplasmsNCT02171637Boehringer Ingelheim38
已完成
1 期
Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsNeoplasmsNCT02171663Boehringer Ingelheim43
已完成
2 期
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant GliomaGliomaNCT00727506Boehringer Ingelheim151
已完成
1 期
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid TumorsSolid Tumors and Hematologic MalignancyNCT00820560Incyte Corporation41
已完成
1 期
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or GefitinibCarcinoma, Non-Small-Cell LungNCT00993499Boehringer Ingelheim44